In this episode of 'Conversations in Lung Cancer Research,' hosted by Associate Professor Mal Itchens, a multidisciplinary panel delves into the ongoing advancements in lung cancer research in Australia and New Zealand. The panel includes Professor Nick Pavlakis from Royal North Shore Hospital and Associate Professor Lauren Troy from Royal Prince Alfred Sydney. Key topics discussed include the 2025 lung cancer screening program, anticipated pharmaceutical benefits scheme (PBS) drug listings for 2026, and the introduction of advanced diagnostic technologies. The conversation highlights the initial impacts of the lung cancer screening program, potential benefits of new ALK inhibitors, and the expanding role of immunotherapy. The episode also explores the future of diagnostic precision with the rise of interventional pulmonology and liquid biopsies. Additionally, it emphasises the growing importance of specialised lung cancer nursing and the integration of novel technologies in oncology practices.

00:00 Introduction to Lung Cancer Research Podcast

00:37 Panel Introduction and Discussion Overview

01:18 Lung Cancer Screening in Australia

02:30 Impact of Screening on Diagnostic Services

06:45 Screening Program Benefits and Challenges

10:34 Future of Lung Cancer Screening

15:54 Advancements in Diagnostic Technology

20:57 Therapeutic Developments in Lung Cancer

24:34 New Drug Listings and Their Impact

40:04 Immunotherapy and Future Directions

44:13 Conclusion and Final Thoughts